Oliver is the Chief Business Officer and a co-founder of Numab. From 2004 until 2010, he was at ESBATech as Head of Alliance Management and responsible for intellectual property. After the acquisition by Alcon in September 2009, Oliver became a member of Alcon’s R&D Alliance Group, tasked with search, evaluation, negotiations and alliance management of collaborations, while remaining Head of Alliance Management at ESBATech, and a member of the ESBATech Management. Oliver studied Molecular Biology and Immunology at the University of Zurich and received his PhD in Biochemistry from the University of Basel in 2004.

Peter is the Chief Medical Officer and is a co-founder of Numab. He holds an MD as well as a PhD in Molecular Biology from the University of Zurich. In 2000 Peter joined ESBATech AG where he led several preclinical and clinical development projects with antibody fragments in oncology, inflammatory and neurodegenerative diseases as the Head of clinical R&D. In particular, he designed the clinical proof-of-concept trial for brolucizumab/Beovu® in wet age-related macular degeneration. In 2011 Peter joined Sucampo Pharmaceuticals, where he became the company’s Chief Medical Officer. In this function, he managed the global clinical development portfolio and held overall responsibility for Medical Affairs and Pharmacovigilance and had numerous interactions with major regulatory agencies as well as HTA bodies, leading to successful NDAs, MAAs and STAs. After the acquisition by Mallinckrodt in 2018, Peter joined Numab as full-time Chief Medical Officer.

Sebastian is Numab’s Chief Operating Officer and oversees the project management, quality assurance, human resource, and support functions. He joined Numab in 2012 to head the engineering and process development group. He is an inventor of the lambda cap™ stable scaffold and MATCH™ multispecific format technologies underlying Numab’s pipeline assets. Before joining Numab, Sebastian was responsible for DSP and analytics development at ESBATech, focusing on novel scFv drug candidates in Phase I/II of clinical development, including brolucizumab/Beovu®. Prior to this, Sebastian was a bioprocess development group leader at Cytos Biotechnology. Sebastian graduated with a degree in Biochemistry from the University of Hamburg and obtained his PhD from the University of Zurich.

Roland is Numab’s Chief Financial Officer and joined Numab in 2011. Prior to his current position, Roland worked for 7 years in the banking industry in Switzerland and Asia with positions in marketing, customer experience management, business process management and information technology. Roland holds a Licenciate in Economics and Business Administration and a Certificate of Advanced Studies in Corporate Finance, both from the University of Zurich.

Dan joined Numab in 2019. He began his career in industry at Oxford Glycosciences, UK in 2002 developing antibody-based therapeutics in the field of Oncology. He then spent 7 years at Genzyme, a Sanofi company, where he helped to establish the antibody therapeutics group of Genzyme in Cambridge, UK. He led the protein engineering and molecular biology teams and was responsible for leading therapeutic programs in oncology and immunology. Dan moved to Switzerland in 2012 and worked for Molecular Partners as VP, Biology and led a team responsible for the preclinical biological characterisation of protein-based therapeutics in immune-oncology, oncology, immunology and ophthalmology. He was also instrumental in collaborations with Roche, Janssen, Allergan and Immunogen. Dan holds a PhD in molecular immunology from the University of Reading and performed a postdoc at the Department of Pharmacology at the University of Oxford, where he studied signalling pathways of platelet activation.

Tea joined Numab in 2011, establishing Numab’s antibody discovery platform. From 2004 to 2011 Tea was Head of PK & PD at ESBATech where she was responsible for the pharmacodynamic and pharmacokinetic characterization of antibody fragments. She led preclinical discovery and development projects in the field of ophthalmology and immuno-oncology. Tea was instrumental in the discovery and the preclinical development of brolucizumab/Beovu® a best-in-class anti-VEGF fragment for the treatment of age-related macular edema. She graduated with a degree in Molecular Biology and Immunology from the University of Zurich and obtained her PhD in Molecular Biology from the University of Zurich.

Tim joined Numab’s Business Development team in 2016, establishing Numab’s formal United States presence in the process. Prior to joining in this capacity, Tim was awarded a PhD in molecular biology from ETH Zurich for work performed in collaboration with Numab. This work entailed researching drug targets, performing antibody discovery campaigns and characterizing Numab’s MATCH® multi-specific antibody format. Prior to that, Tim worked as an epidemiologist focusing on international development in sub-Saharan Africa and received an MSc in epidemiology from the London School of Hygiene & Tropical Medicine in 2011.

Stefan is responsible for the CMC activities at Numab including protein engineering, analytics, and formulation, USP and DSP development. In his role as project lead, he further managed Numab’s lead program ND021 until FIM. Before joining Numab in 2015, Stefan worked in the pharmaceutical development at CSL Behring, focusing on process development and optimization to support clinical production and up-scaling. Stefan studied biochemistry in Tübingen and Zurich and graduated with a degree in Biochemistry from the ETH Zurich and obtained his PhD in Structural Biology and Biochemistry from the University of Zurich.

Dr. Daniel Vasella, served as Chairman of Novartis AG, a leading global medicines company, from 1999 until 2013 and as Chief Executive Officer of Novartis AG from 1996 to January 2010. From 1992 to 1996, Dr. Vasella held the positions of Chief Executive Officer, Chief Operating Officer, Senior Vice President and Head of Worldwide Development and Head of Corporate Marketing at Sandoz Pharma Ltd. He also served at Sandoz Pharmaceuticals Corporation from 1988 to 1992. Dr. Vasella is currently working as a coach to senior executives. He is also a director of PepsiCo and American Express Company, and is a member of several non-profit organizations.

Dr. Zhu has extensive research and development experience within the biotechnology industry. Since 2017 Dr. Zhu is acting as Chief Scientific Officer at 3SBio. Before he served as Executive Vice President, Global Biopharmaceuticals, Kadmon Corporation, and President of Kadmon China. Prior to joining Kadmon, Dr. Zhu was Vice President and Global Head, Protein Sciences and Design, at Novartis and was responsible for the discovery, design and selection of novel biologics medicines that address various human diseases. Prior to Novartis, Dr. Zhu worked for over 12 years at ImClone Systems as Vice President of Antibody Technology and Immunology, and has led multiple teams responsible for the  successful discovery and early development of  several FDA-approved novel antibodies for various oncology indications, including cetuximab (Erbitux®), ramucirumab (Cyramza®), necitumumab (Portrazza®), and olaratumab (Latruvo®). Dr. Zhu is the inventor of both ramucirumab and necitumumab, and one of the major contributors to cetuximab and olaratumab.

Mark Egan is an investment-banking veteran who between 1962 and 1989 made his career at Hornblower & Weeks, Kuhn Loeb & Co, and Lehman Brothers. Since 1989 Mark is president, chairman and owner of Marlin Capital. Marlin Capital is the general partner of the Private Investment Fund of which Mark is the largest limited partner.

Ignacio Melero, M.D., Ph.D., is professor of immunology at the Academic Hospital of Navarra and at the Center for Applied Medical Research (CIMA) of the University of Navarra. He leads a group working in translational tumor immunotherapy with emphasis on cell therapy, cytokine gene therapy, and immune-stimulatory monoclonal antibodies. Earlier in his career, Dr. Melero contributed to seminal discoveries in the function Natural Killer cells, and T-cell co-stimulation via CD137 (4-1BB). Dr. Melero has been awarded the BIAL Prize of Medicine, the Conde de Cartagena Award from the Royal Academy of Medicine, Doctor Durantez LAIR Foundation Award and a CRI research award. He has served on advisory boards of Bristol Myers-Squibb, Roche-Genentech, AstraZeneca, Merck Serono and Boehringer Ingelheim, and holds research grants by Pfizer, Bristol Myers Squibb, and Alligator.

Mario Sznol, M.D., is a Professor of Medicine (Medical Oncology). Dr. Sznol, formerly with the National Cancer Institute, has an international reputation in cancer drug development. Dr. Sznol’s expertise and experience is in cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is working to expand the opportunities for clinical trials at the Yale Cancer Center, particularly those focusing on immunotherapy and novel agents.

David Hong, M.D., is a Professor of Medicine and the Associate Vice President of Clinical Research at MD Anderson Cancer Center. Throughout his career, Dr. Hong has developed an interest in studying the efficacy of novel drug combinations in patients with solid tumors. Recently his research endeavors have focused on developing personalized therapies for patients, whose tumors bear specific genetic mutations/amplifications and combining targeted therapies with immunotherapies.

Matthew Galsky, M.D., is a Professor of Medicine, Hematology and Medical Oncology and a Professor of Urology at the Icahn School of Medicine at the Mount Sinai Health Systems hospitals in New York. Dr. Galsky also serves as Director of Genitourinary Medical Oncology at the Tisch Cancer Institute. He specializes in the care of patients with genitourinary malignancies (i.e. bladder and kidney cancer). His research focuses on the development of novel treatments for these cancers, and Dr. Galsky uses team-science based approaches to understand sensitivity and resistance to such therapies.

Robert L. Ferris, M.D., Ph.D. is the Director of the UPMC Hillman Cancer Center of the University of Pittsburgh, where he is a Professor of Oncology and Immunology and a Co-Director of the Tumor Microenvironment Center. Dr. Ferris is a leading expert in the immuno-biology and treatment of head and neck cancer. He has been the principal investigator in multiple Phase I-III clinical trials and his research is focused on cellular immune mechanisms of natural killer (NK) cells, dendritic cells, and T lymphocyte activation against head and neck cancer tumor antigens.